Kazia Therapeutics Ltd (ASX:KZA) chief executive officer James Garner speaks to Proactive Investors about new safety and tolerability data from the company's phase-IIa clinical trial of brain cancer treatment.
Garner said the superior results from the ongoing study of GDC-0084 in newly diagnosed glioblastoma patients was an important milestone for the company.
He added the current, second stage of the two-part study (which began in September) will transition into observing more patients, with higher doses of the drug.
Meet Cardinal Resources Ltd and Legend Mining Ltd at our event, Melbourne , 16 July 2019. Register here »